PDG12 Cost-Effectiveness Analysis of Olaparib for Metastatic Castration Resistant Prostate Cancer Patients with at Least one Mutation in Genes BRCA1, BRCA2, or ATM
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.460
https://www.valueinhealthjournal.com/article/S1098-3015(21)00677-X/fulltext
Title :
PDG12 Cost-Effectiveness Analysis of Olaparib for Metastatic Castration Resistant Prostate Cancer Patients with at Least one Mutation in Genes BRCA1, BRCA2, or ATM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00677-X&doi=10.1016/j.jval.2021.04.460
First page :
Section Title :
Open access? :
No
Section Order :
11017